Danielle Duffy

发表

Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport

D. Rader, Danielle Duffy, 2005, Current opinion in cardiology.

Pharmacokinetics and Safety of CSL112 (Apolipoprotein A‐I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function

S. Wright, M. Tortorici, A. Gille, 2018, Clinical pharmacology in drug development.

Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport.

D. Rader, Danielle Duffy, 2006, Circulation.

ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future

P. Libby, A. Shaunik, P. Ridker, 2022, Current Atherosclerosis Reports.

High-density lipoprotein cholesterol therapies: the next frontier in lipid management.

D. Rader, Danielle Duffy, 2006, Journal of cardiopulmonary rehabilitation.

Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome

M. Reilly, D. Rader, F. Samaha, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity

L. Deckelbaum, S. Wright, M. Tortorici, 2018, Journal of clinical pharmacology.

A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.

E. Antonarakis, M. Carducci, T. Force, 2013, American journal of cancer therapy and pharmacology.

Impact of the MTP Inhibitor AEGR-733 on Pharmacokinetics of Statins

D. Rader, W. Sasiela, R. Movva, 2007 .

Impact of high doses of the MTP-Inhibitor, AEGR-733, on the single dose Pharmacokinetics of Atorvastatin and Rosuvastatin

D. Rader, W. Sasiela, L. Bloedon, 2007 .

US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry.

Emily C. O'Brien, J. Knowles, D. Rader, 2016, Journal of clinical lipidology.

Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome

D. Rader, R. Movva, L. Bloedon, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Potent and Selective PPAR-Agonist LY 518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome

D. Rader, R. Movva, L. Bloedon, 2008 .

Update on strategies to increase HDL quantity and function

D. Rader, Danielle Duffy, 2009, Nature Reviews Cardiology.

Oral Apolipoprotein A‐I Mimetic D‐4F Lowers HDL‐Inflammatory Index in High‐Risk Patients: A First‐in‐Human Multiple‐Dose, Randomized Controlled Trial

R. B. Norris, D. Rader, R. Movva, 2017, Clinical and translational science.

ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future

P. Libby, A. Shaunik, P. Ridker, 2022, Current Atherosclerosis Reports.

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity

B. Kingwell, C. Gibson, S. Nicholls, 2022, Journal of the American Heart Association.

Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison

S. Goto, C. Gibson, P. Dalitz, 2022, Clinical and translational science.

Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients

P. Tricoci, S. Wright, M. Tortorici, 2020, British journal of clinical pharmacology.

CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial

L. Deckelbaum, C. Gibson, S. Wright, 2022, Journal of cardiovascular pharmacology and therapeutics.

Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry

Emily C. O'Brien, J. Knowles, D. Rader, 2016, Circulation. Cardiovascular genetics.

The CSL112–2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A‐I [human]), an intravenous formulation of plasma‐derived apolipoprotein A‐I, among subjects with moderate renal impairment after acute myocardial infarction

B. Lewis, R. Mehran, C. Bode, 2019, American heart journal.

The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction.

E. Peterson, M. Roe, D. Holmes, 2012, American heart journal.

Aspirin for Cardioprotection and Strategies to Improve Patient Adherence

D. Whellan, Geoffrey D. Mills, Danielle Duffy, 2014, Postgraduate medicine.

Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis

Deepak L. Bhatt, A. Shaunik, R. Yeh, 2021, Frontiers in Cardiovascular Medicine.

Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

L. Deckelbaum, P. Ridker, S. Pocock, 2020, American heart journal.

Targeting Lipoprotein (a): an Evolving Therapeutic Landscape

Danielle Duffy, Erik M. Kelly, Li Man, 2015, Current Atherosclerosis Reports.

Novel Treatments for Familial Hypercholesterolemia: Pharmacogenetics at Work

J. Ross, J. Marbach, Danielle Duffy, 2014, Pharmacotherapy.

Abstract 1496: Oral Administration of the Apolipoprotein A-I Mimetic Peptide D-4F in Humans with CHD Improves HDL Anti-Inflammatory Function After a Single Dose

D. Rader, M. Navab, L. Bloedon, 2006 .

Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity.

D. Rader, Danielle Duffy, 2007, Trends in cardiovascular medicine.

PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers

D. Whellan, Danielle Duffy, S. Adams, 2014, Expert review of cardiovascular therapy.

Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.

D. Whellan, Jad Al Danaf, A. Panakos, 2016, American heart journal.

Abstract: P469 IMPACT OF HIGH DOSES OF THE MTP-INHIBITOR, AEGR-733, ON THE SINGLE DOSE PHARMACOKINETICS OF ATORVASTATIN AND ROSUVASTAIN

D. Rader, W. Sasiela, L. Bloedon, 2009 .

2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk.

Danielle Duffy, Jonathan B. Finkel, 2015, Trends in cardiovascular medicine.

Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath hold.

N. Simone, A. Dicker, P. Anné, 2015, Practical radiation oncology.

Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia

R. Movva, L. Bloedon, S. Tuteja, 2014, Pharmacotherapy.

Abstract 12169: LDL-C Levels and Treatment Patterns Among Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry

J. Knowles, D. Rader, C. Ballantyne, 2015 .

Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction

P. Ridker, R. Mehran, B. Kingwell, 2021, European heart journal. Cardiovascular pharmacotherapy.

Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction

P. Ridker, R. Mehran, B. Kingwell, 2023, European heart journal. Cardiovascular pharmacotherapy.

CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post–Myocardial Infarction

B. Kingwell, C. Gibson, S. Wright, 2023, Arteriosclerosis, thrombosis, and vascular biology.